Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia

Cancer cell cycle inhibitor is Lin BioScience's second candidate to receive Orphan Drug Designation SAN DIEGO, April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Lin BioScience, a drug development company targeting unmet clinical needs in onco... Biopharmaceuticals, Oncology, FDA Lin BioScience, LBS-007, acute lymphoblastic leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Brown PA, Shah B Abstract Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:...
Source: Los Angeles Times - Science - Category: Science Authors: Source Type: news
LONDON (CBS Local) – A groundbreaking study into what triggers cancer has found that children who are “too hygienic” and are kept away from other kids were at greater risk for developing leukemia. The Details: A cancer study has found that children living in ultra-clean environments have higher rates of leukemia Professor Mel Greaves says children need to have their immune system “primed” by exposure to various germs Greaves found that children with siblings or who were breastfed had lower rates of the disease Professor Mel Greaves from the Institute of Cancer Research (ICR) in London h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News childhood cancer Children Chris Melore Germs Leukemia Local TV talkers Source Type: news
Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial, Published online: 22 May 2018; doi:10.1038/s41408-018-0084-5Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
(Institute of Cancer Research) A major new analysis reveals the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins.Professor Mel Greaves assessed the most comprehensive body of evidence ever collected on acute lymphoblastic leukaemia (ALL). He concludes the disease is caused through a two-step process of genetic mutation and exposure to infection that means it may be preventable with treatments to stimulate or 'prime' the immune system in infancy.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Acute lymphoblastic leukemia (ALL) is the white blood cell cancer in children. L-asparaginase (L-ASNase) is one of the first drugs used in ALL treatment. Anti-tumor activity of L-ASNase is not specific and indicates limited stability in different biological environments, in addition to its quick clearance from blood. The purpose of the present study was to achieve a new L-ASNase polymer bioconjugate to improve pharmacokinetic, increase half-life and stability of the enzyme. The conjugations were achieved by the cross-linking agent of 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide (EDC) which activates the carboxylic acid ...
Source: IET Nanobiotechnology - Category: Nanotechnology Source Type: research
Cytogenetic heterogeneities including additional chromosomal abnormalities (ACAs) are frequently observed in adults with t(9;22)(q34.1;q11.2)/BCR-ABL1 positive B cell acute lymphoblastic leukemia (Ph+B-ALL). We retrospectively investigated such heterogeneities/ACAs in 144 adults with Ph+B-ALL to assess their clinical implications. There were 85 (59.1%) men and 59 (40.9%) women with a median age of 54-years. Patients were sorted into 6 subgroups based on the karyotypic findings in stemline including: 32 (22.2%) with t(9;22) as the sole aberration, 23 (15.9%) with t(9;22) plus one ACA, 26 (18.1%) with t(9;22) as part of a co...
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
This study examined mechanisms for this resistance, including protective effects conferred by bone marrow stromal components. T cell acute leukemia cells co-cultured with mesenchymal stem cells demonstrated significantly enhanced survival against parthenolide (73+/-11%) compared to cells treated without mesenchymal stem cell support (11+/-9%). Direct cell contact between mesenchymal cells and leukemia cells was not required to afford protection from parthenolide. Mesenchymal stem cells released thiols and protected leukemia cells from reactive oxygen species stress, which is associated with parthenolide cytotoxicity. Block...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Publication date: August 2018 Source:Cancer Genetics, Volumes 224–225 Author(s): Xinyan Lu
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Marketing | Pharmaceuticals